Zacks Investment Research upgraded shares of Hill-Rom (NYSE:HRC) from a hold rating to a buy rating in a report published on Tuesday morning, Zacks.com reports. They currently have $118.00 target price on the medical technology company’s stock.
According to Zacks, “Hill-Rom saw a solid year-over-year increase in revenues on robust domestic growth, driven by sturdy performance by Patient Support Systems and Front Line Care in the last reported quarter. The company has recorded around $100 million in new product revenues in the quarter. We are also upbeat about Hill-Rom’s integration of EarlySense’s continuous contact-free heart rate and respiratory rate sensing and analytics technology with its Centrella Smart+ bed platform in the reported quarter. Also, the tie-up with Microsoft to make advanced, relevant and actionable point-of-care data and solutions buoys optimism. Overall, Hill-Rom has outperformed its industry in the past six months. However, foreign exchange and a tough competitive landscape remain headwinds. Also, Hill-Rom’s global revenues declined in the quarter.”
Other analysts also recently issued reports about the company. Barclays boosted their target price on Hill-Rom from $103.00 to $108.00 and gave the stock an equal weight rating in a research report on Monday. Needham & Company LLC reiterated a buy rating and set a $116.00 target price on shares of Hill-Rom in a research report on Monday, March 11th. ValuEngine upgraded Hill-Rom from a hold rating to a buy rating in a research report on Saturday, January 19th. Finally, Morgan Stanley decreased their target price on Hill-Rom from $100.00 to $98.00 and set an equal weight rating on the stock in a research report on Wednesday, January 2nd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $109.88.
Hill-Rom stock opened at $101.00 on Tuesday. The company has a current ratio of 1.70, a quick ratio of 1.25 and a debt-to-equity ratio of 1.17. Hill-Rom has a 1-year low of $81.82 and a 1-year high of $108.68. The company has a market capitalization of $7.04 billion, a P/E ratio of 21.26, a price-to-earnings-growth ratio of 1.82 and a beta of 0.95.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings results on Friday, January 25th. The medical technology company reported $1.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.98 by $0.04. Hill-Rom had a return on equity of 21.23% and a net margin of 7.21%. The firm had revenue of $683.50 million for the quarter, compared to the consensus estimate of $676.39 million. During the same period in the previous year, the business earned $0.92 earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities analysts anticipate that Hill-Rom will post 5.04 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 22nd were given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.83%. This is an increase from Hill-Rom’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Thursday, March 21st. Hill-Rom’s payout ratio is presently 17.68%.
A number of institutional investors and hedge funds have recently bought and sold shares of HRC. Oregon Public Employees Retirement Fund lifted its position in shares of Hill-Rom by 8,755.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 2,308,056 shares of the medical technology company’s stock valued at $26,000 after acquiring an additional 2,281,991 shares in the last quarter. Norges Bank purchased a new stake in shares of Hill-Rom in the fourth quarter valued at $66,335,000. Bank of New York Mellon Corp lifted its position in shares of Hill-Rom by 27.0% in the fourth quarter. Bank of New York Mellon Corp now owns 1,038,521 shares of the medical technology company’s stock valued at $91,961,000 after acquiring an additional 220,981 shares in the last quarter. BlackRock Inc. lifted its position in shares of Hill-Rom by 3.5% in the fourth quarter. BlackRock Inc. now owns 6,350,899 shares of the medical technology company’s stock valued at $562,371,000 after acquiring an additional 215,770 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in shares of Hill-Rom by 179.2% in the third quarter. Marshall Wace LLP now owns 332,231 shares of the medical technology company’s stock valued at $31,363,000 after acquiring an additional 213,243 shares in the last quarter. Institutional investors own 85.15% of the company’s stock.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
See Also: What is a Stop Order?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.